GLUE vs. NOVO-B.CO
Compare and contrast key facts about Monte Rosa Therapeutics, Inc. (GLUE) and Novo Nordisk A/S (NOVO-B.CO).
Performance
GLUE vs. NOVO-B.CO - Performance Comparison
Loading graphics...
GLUE vs. NOVO-B.CO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
GLUE Monte Rosa Therapeutics, Inc. | 9.50% | 125.94% | 22.83% | -25.76% | -62.73% | -3.59% |
NOVO-B.CO Novo Nordisk A/S | -25.78% | -39.54% | -15.04% | 55.49% | 22.06% | 36.60% |
Different Trading Currencies
GLUE is traded in USD, while NOVO-B.CO is traded in DKK. To make them comparable, the NOVO-B.CO values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, GLUE achieves a 9.50% return, which is significantly higher than NOVO-B.CO's -25.78% return.
GLUE
- 1D
- 4.38%
- 1M
- -7.19%
- YTD
- 9.50%
- 6M
- 128.93%
- 1Y
- 287.58%
- 3Y*
- 30.14%
- 5Y*
- —
- 10Y*
- —
NOVO-B.CO
- 1D
- 2.84%
- 1M
- 2.36%
- YTD
- -25.78%
- 6M
- -34.10%
- 1Y
- -44.56%
- 3Y*
- -20.52%
- 5Y*
- 3.75%
- 10Y*
- 5.41%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GLUE vs. NOVO-B.CO — Risk / Return Rank
GLUE
NOVO-B.CO
GLUE vs. NOVO-B.CO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and Novo Nordisk A/S (NOVO-B.CO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GLUE | NOVO-B.CO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.03 | -0.79 | +3.82 |
Sortino ratioReturn per unit of downside risk | 3.99 | -0.93 | +4.92 |
Omega ratioGain probability vs. loss probability | 1.46 | 0.87 | +0.59 |
Calmar ratioReturn relative to maximum drawdown | 6.45 | -0.80 | +7.25 |
Martin ratioReturn relative to average drawdown | 15.56 | -1.39 | +16.95 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| GLUE | NOVO-B.CO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.03 | -0.79 | +3.82 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.10 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.16 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.04 | 0.43 | -0.47 |
Correlation
The correlation between GLUE and NOVO-B.CO is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
GLUE vs. NOVO-B.CO - Dividend Comparison
GLUE has not paid dividends to shareholders, while NOVO-B.CO's dividend yield for the trailing twelve months is around 4.94%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GLUE Monte Rosa Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NOVO-B.CO Novo Nordisk A/S | 4.94% | 3.58% | 1.59% | 1.01% | 1.19% | 1.27% | 2.02% | 2.11% | 2.64% | 2.27% | 3.69% | 1.25% |
Drawdowns
GLUE vs. NOVO-B.CO - Drawdown Comparison
The maximum GLUE drawdown since its inception was -94.08%, which is greater than NOVO-B.CO's maximum drawdown of -74.86%. Use the drawdown chart below to compare losses from any high point for GLUE and NOVO-B.CO.
Loading graphics...
Drawdown Indicators
| GLUE | NOVO-B.CO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.08% | -76.75% | -17.33% |
Max Drawdown (1Y)Largest decline over 1 year | -41.84% | -54.94% | +13.10% |
Max Drawdown (5Y)Largest decline over 5 years | — | -76.75% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -76.75% | — |
Current DrawdownCurrent decline from peak | -59.32% | -75.38% | +16.06% |
Average DrawdownAverage peak-to-trough decline | -75.30% | -15.80% | -59.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.36% | 32.14% | -14.78% |
Volatility
GLUE vs. NOVO-B.CO - Volatility Comparison
Monte Rosa Therapeutics, Inc. (GLUE) has a higher volatility of 14.86% compared to Novo Nordisk A/S (NOVO-B.CO) at 9.70%. This indicates that GLUE's price experiences larger fluctuations and is considered to be riskier than NOVO-B.CO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| GLUE | NOVO-B.CO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.86% | 9.70% | +5.16% |
Volatility (6M)Calculated over the trailing 6-month period | 63.99% | 41.71% | +22.28% |
Volatility (1Y)Calculated over the trailing 1-year period | 95.74% | 57.00% | +38.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 102.66% | 39.06% | +63.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 102.66% | 33.04% | +69.62% |
Financials
GLUE vs. NOVO-B.CO - Financials Comparison
This section allows you to compare key financial metrics between Monte Rosa Therapeutics, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities